Hepatitis C Combination Therapy - Dynavax hepatitis vaccine shows promise

Dynavax hepatitis vaccine shows promise
BusinessWeek - DEC. 19 9:09 A.M. ET Dynavax Technologies Corp., a biopharmaceutical focused on treatments for allergies, infectious and chronic inflammatory diseases, said Monday a mid-stage trial of its hepatitis B virus, or HBV, vaccine was successful, warranting

What's New in Hepatitis C: Current State of the Field and Future
Medscape News - The current standard of care for the treatment of previously untreated patients with chronic hepatitis C is a combination of once-weekly injection of pegylated interferon plus daily oral ribavirin. The treatment duration is dependent on HCV genotype

Thousands infected with hepatitis C
999 Today - Around 4,500 people in England and Wales are living with severe liver disease, including cirrhosis, liver failure or liver cancer, as a result of having a chronic hepatitis C infection, a new report has found. The Health Protection Agency (HPA